Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Xpress
The findings provide significant conceptual advances into cancer neuroscience and establish therapeutic avenues that are distinct from present amyloid-lowering strategies, aiming at degrading the existing amyloid plaques.
Geriatrics February 2nd 2026
MDLinx
“Although historically grouped together, viral-associated PCNSL subtypes are biologically distinct diseases. Each escapes immune control through a different mechanism, creating fundamentally different tumor microenvironments.” – Melinda Burgess, Researcher from the Department of Haematology at Princess Alexandra Hospital
Hematology January 20th 2026
Medical News Today (MNT)
In neuro-oncology, where many of the therapies are expensive, toxic, and difficult to access, the idea that a low-cost, generic medication might help slow a tumor like glioblastoma is extremely attractive.
Neurology December 1st 2025
Neuro-Oncology
Long-term follow-up data demonstrate a significant overall survival advantage with combination therapy, showing a hazard ratio of 0.54 (95% CI 0.31-0.95) for radiation plus temozolomide versus radiation alone in grade II gliomas.
Neurology February 20th 2025